Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

INO-9112

Other · developed by INOVIO PHARMACEUTICALS

Phase 1 Most advanced trial (none active)
INO Developer
1 Registered trials

What is INO-9112?

INO-9112 is an investigational drug studied in Coronavirus Infection.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
INOVIO PHARMACEUTICALS (INO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05430958 Phase 1 Coronavirus Infection Withdrawn INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Coronavirus Infection

More from INOVIO PHARMACEUTICALS

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Phase 1 INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3107 Phase 1/2 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind INO-9112

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.